Rybrevant underwhelms in Mariposa, handing a possible advantage back to AstraZeneca’s Tagrisso.

And first data with a low dose are particularly unimpressive.

Leaked data ahead of the ESMO late breaker show a progression-free survival benefit that looks practice-changing.

The latest first-in-human trial entrants include several novel mechanisms, a PSMA radioconjugate and a new pan-KRAS challenger.

Phase 1 data suggest the group’s KRAS G12C inhibitor has activity, crucially in KRAS-experienced patients. 

Initial data on Amgen’s AMG 193 give some Tango investors a headache.